Springer, one of the leading publishers in the fields of science, technology and medicine, has signed an agreement with The Endocrine Society to co-publish a new journal, Hormones & Cancer, starting in January 2010. Hormonal cancers include two of the most deadly cancer subtypes, cancers of the breast and prostate. In addition to these cancers, Hormones & Cancer will include research articles covering other less-commonly occurring cancer subtypes, such as thyroid, gynecologic and pituitary cancer. The journal will help to bridge the gap between those working in the two often disconnected fields of endocrinology and cancer research.
Hormones & Cancer will be a true translational journal, including basic scientific, epidemiological and clinical research papers. Because of the inherent multidisciplinary nature of the field, it is anticipated that the journal's focus will be on all aspects of hormone action on cancer causation, progression, dependence, prevention, resistance and treatment. Translational studies, especially those utilizing novel cancer agents selectively designed to exert their action at hormone target tissues, will also be welcomed.
Springer and The Endocrine Society have worked together to create a highly respected, international editorial board that includes many of the leaders in this interdisciplinary field. The editor-in-chief will be Jonathan Li of the Department of Pharmacology, Toxicology, and Therapeutics at Kansas University School of Medicine in Kansas City, Kansas. Board members include V. Craig Jordan, the first to discover the breast cancer prevention properties of tamoxifen, and Kate Horwitz, Distinguished Professor of Endocrinology, Metabolism, and Diabetes at the University of Colorado Denver, and Past President of The Endocrine Society.
"The timing of this journal's launch could not be better," said Kate Horwitz. "The disciplines of endocrinology and oncology have been artificially segregated for years. This is evident in factors as disparate as the divisional structure of departments of medicine and the layout of granting agency review panels. Cancers of hormone-producing organs, and of organs that are the targets of hormones, represent a large and diverse group. Hormones & Cancer will now link them."
"We are pleased to add Hormones & Cancer to The Endocrine Society's family of journals. It will create a home for this important field of research, which is a focus of many of our members, and a concern for our practitioners and their patients," commented Margaret Shupnik, Publications Core Committee Chair, The Endocrine Society.
Henk van der Rijst, Executive Vice President, Biomedical and Life Sciences at Springer, said: "Working with a prestigious society to disseminate critical information more widely is one of our core activities. Springer looks forward to a long and collaborative partnership with The Endocrine Society."
Hormones & Cancer will be published bimonthly both electronically and in print. The journal will include Cross Reference Linking, alert services, and Online First™, a feature by which articles are published online before they appear in print. The journal will be available on SpringerLink.com, the world's most comprehensive collection of scientific, technological, and medical journals, books and reference works.
Founded in 1916, The Endocrine Society (www.endo-society.org) is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. It is an international body, with 14,000 members from over 100 countries. The Endocrine Society publishes four world-renowned journals and a monthly news magazine. It also holds scientific conferences, provides educational programs for physicians, issues clinical practice guidelines and promotes careers in endocrinology. The Society advocates for appropriate funding of scientific research in endocrinology and public policies that support the practice of clinical endocrinology.
Springer (www.springer.com) is a leading global scientific publisher of books and journals, delivering quality content through innovative information products and services. It publishes close to 500 academic and professional society journals. Springer is part of the publishing group Springer Science+Business Media. In the science, technology and medicine (STM) sector, the group publishes around 2,000 journals and more than 6,500 new books a year, as well as the largest STM eBook Collection worldwide. Springer has operations in about 20 countries in Europe, the USA, and Asia, and more than 5,000 employees.
Hormones & Cancer
ISSN: 1868-8497 (print version), ISSN: 1868-8500 (electronic version)